Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,997,341 papers from all fields of science
Search
Sign In
Create Free Account
Refractory Mantle Cell Lymphoma
Known as:
Mantle Cell Lymphoma Refractory
Mantle cell lymphoma resistant to treatment.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
22 relations
Atypical lymphocyte
B lymphoblast
B-Lymphocytes
CCND1 gene
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Treating MCL with CAR T Cells.
Cancer Discovery
2020
Corpus ID: 215809127
KTE-X19, an investigational chimeric antigen receptor T-cell therapy, has shown promising efficacy in patients with relapsed…
Expand
Review
2020
Review
2020
FDA Grants Priority Review to KTE-X19 for Treatment of Mantle Cell Lymphoma
H. Slater
2020
Corpus ID: 213974474
The biologic license application is supported by data from the phase II ZUMA-2 trial, which is currently assessing the CAR T-cell…
Expand
2015
2015
Treatment of recurrent refractory mantle cell lymphoma by thalidomide in combination with interferon
Li-Jie Han
,
Hui-Fang Zhao
,
Q. Yin
,
Lin Chen
,
Yong-Ping Song
,
Xu-Dong Wei
2015
Corpus ID: 78294054
Mantle cell lymphoma (MCL) is a highly aggressive non-Hodgkin's lymphoma with poor prognosis. This study aims to explore a new…
Expand
2015
2015
Impact of prior treatment on PFS for relapsed/refractory mantle cell lymphoma patients randomized to lenalidomide vs investigator's choice: a subgroup analysis of the phase II Mcl-002 (Sprint) study.
M. Trněný
,
T. Lamy
,
+11 authors
L. Arcaini
2015
Corpus ID: 73904547
2014
2014
Cancer Therapy : Preclinical Antitumoral Activity of Lenalidomide in In Vitro and In Vivo ModelsofMantleCell Lymphoma Involves theDestabilization of Cyclin D 1 / p 27 KIP 1 Complexes
A. Moros
,
S. Bustany
,
+4 authors
B. Sola
2014
Corpus ID: 5685592
Purpose: Clinical responses to the immmunomodulatory drug lenalidomide have been observed in patients with relapsed/refractory…
Expand
2013
2013
relapsed/refractory mantle cell lymphoma Anti-tumor activity of rituximab plus thalidomide in patients with
C. Zielinski
,
A. Chott
,
+5 authors
A. Bankier
2013
Corpus ID: 68474526
Review
2012
Review
2012
[Thalidomide combined with interferon in relapsed or refractory mantle cell lymphoma: two cases report and literatures review].
Hui-Fang Zhao
,
Xu-Dong Wei
,
Q. Yin
Zhonghua xue ye xue za zhi = Zhonghua xueyexue…
2012
Corpus ID: 29012262
OBJECTIVE To investigate JAK2 exon 12 mutations in patients with Philadelphia (Ph) chromosome-negative myeloproliferative…
Expand
2011
2011
A multicenter phase II study (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
C. Renner
,
P. Zinzani
,
+14 authors
N. Ketterer
2011
Corpus ID: 198265253
Introduction: Mantle cell lymphoma (MCL) accounts for 6% of all B-cell lymphomas and is in most cases an incurable disease. It is…
Expand
2010
2010
Concurrent involved field radiation therapy and Temsirolimus in refractory mantle cell lymphoma (MCL)
Y. Kirova
,
Cyrus Chargari
,
M. Amessis
,
J. Vernant
,
N. Dhédin
American journal of hematology/oncology
2010
Corpus ID: 46261286
Temsirolimus, an inhibitor of mammalian target of rapamycin, has antitumor activity and improves progress-free survival in…
Expand
2010
2010
A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis.
V. Morrison
,
Jeffrey L. Johnson
,
Sin-Ho Jung
,
J. Leonard
,
B. Cheson
2010
Corpus ID: 70873647
8106 Background: Despite high response rates to initial therapy for MCL, patients (pts) typically relapse and novel approaches…
Expand